Nexus Biopharma Inc., of Montclair, N.J., formerly Plata Resources Inc., said it completed its merger with Nexus Biopharma Inc., a company developing an obesity drug targeting the AMPK metabolic pathway. As a publicly operating company, the life sciences firm said its access to capital markets will enable it to complete drug optimization and pre-investigational new drug application studies to move toward clinical testing.